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Abstract 
 
Chronic liver disease is a disease process of the liver that involves progressive destruction and regeneration of the 
liver parenchyma leading to fibrosis and cirrhosis. We first evaluated the 70 percutaneous liver biopsies from 
patients with a clinically established diagnosis of chronic hepatitis and chronic liver diseases of various etiologies. 
All biopsies were obtained through percutaneous approach using 16 F biopsy gun (manufactured by Bard) in adults 
and 18 F in children. . The mean biopsy size was 1.8cm ± 0.20 and a median size was 2cm. Out of the 70 liver 
biopsies, a total of 24 (34.2%) liver biopsies were less than 1.5cm in size, and 46(65.7%) were ≥ 1.5cm. 
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Introduction  
Chronic liver disease is a disease process of the liver 
that involves progressive destruction and regeneration 
of the liver parenchyma leading to fibrosis and 
cirrhosis. Chronic liver disease (CLD) is the major 
cause of morbidity and mortality worldwide. More 
recently, the increasing prevalence of obesity and the 
metabolic syndrome has resulted in increasing 
incidence of cirrhosis secondary to nonalcoholic fatty 
liver disease (NAFLD), especially in developed 
countries[1]. Viral hepatitis is the most common cause 
of acute and chronic liver disease in the world with 
over half the world’s population exposed to the 
different hepatotropic viruses[2].Approximately 18% 
of patients with auto-immune liver disease present with 
features characteristic of a second auto-immune 
hepatobilliary disease, usually Primary Biliary 
Cirrhosis (PBC) or Primary Sclerosing Cholangitis 
(PSC)[3]. Inspite of recent advances in non-
invasivetechniques, liver biopsy continues to be the 
gold standard method in evaluating chronic hepatitis 
and fibrosis[4]. 
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Materials & methods 
This was a prospective study carried out over a period 
of 2 years extending from June 2013 to June 2015. 
We first evaluated the 70 percutaneous liver biopsies 
from patients with a clinically established diagnosis of 
chronic hepatitis and chronic liver diseases of various 
etiologies. All biopsies were obtained through 
percutaneous approach using 16 F biopsy gun 
(manufactured by Bard) in adults and 18 F in children. 
All samples ≥ 1.5cm were reviewed blindly at two 
different sessions, changing the length of the sample 
with the aid of opaque paper tape [Artificial Sampling, 
(AS)]so that only specific specimen lengths (5 mm, 
10mm) were visible. All the parameters including the 
diagnosis, scoring and staging of the various diseases 
were repeated by reducing the length of the specimen 
from ≥1.5 cm to 1 cm (AS1) and further to 0.5cm 
(AS2). The Ishak’s scoring system[5] was used for 
grading and staging of chronic hepatitis. For NASH, 
Kleiner’s score was used and staging in primary biliary 
cirrhosis was done by Ludwig’s method[6,7]. 
Statistical analysis 
For assessing the impact of length on the scoring and 
fibrosis, agreement between the 5-mm, 10-mm, with 
the 15-mm or greater length was estimated by using 
weighted κ statistics. The statistical evaluation was 
based on the prerequisite that the biopsy length of 
1.5cm or greater was the gold standard, and that 
smaller biopsy specimens were compared with that 
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gold standard. The interpretation of the magnitude of 
the weighted κ score is that greater than 0.75 signifies 
excellent agreement, the closer to 1.0 the greater the 
agreement; and less than 0.40 indicates poor 
agreement[8]. 
 
Results 
. The mean biopsy size was 1.8cm ± 0.20 and a median 
size was 2cm. Out of the 70 liver biopsies, a total of 24 
(34.2%) liver biopsies were less than 1.5cm in size, and 
46(65.7%) were ≥ 1.5cm. 
 Histopathological Diagnosis 
Out of the 70 liver biopsies,27(38.6%) were reported as 
chronic hepatitis which was the most common 
histopathological diagnosis made, followed by PBC 
which was seen in 6(8.5%) biopsies. The other 
histopathological diagnoses made included cirrhosis in 
6(8.5%), cholestatic hepatitis in 5(7.2%), non-alcoholic 
steatohepatitis (NASH) in 6(8.5%), glycogen storage 
disease in 5(7.2%),AIH-PBC overlap in 4(5.7%), AIH 
in 3(4.28%),Wilson’s disease in 2(2.9%) biopsies. 
1(1.4%) case reported was uncertain for NASH. 
Because of inadequate size, diagnosis was not possible 
in 5(7.2%) liver biopsies.12 out of 13 biopsies of 
AIH/PBC were from female patients. The other 
diseases however showed no particular gender 
distribution. 
Impact of length of liver biopsy on the number of 
complete portal tracts 
Artificial sampling at 1cm could be done in 46 liver 
biopsies (which were ≥ 1.5cm in size). The number of 
complete portal tracts in these biopsies ranged from of 
a minimum of 1 to a maximum of 6 and overall a 
decrease in the number of CPTs was observed in 
41(93.1%) biopsies.In 5(10.8%) biopsies, the number 
of complete portal tracts remained the same.The mean 
number of CPTs reduced from 7.07 ± 1.73 to 4.46 ± 
1.20.(Chart 1). Table 1 shows comparison of 
complete portal tracts from liver biopsies 1.5cm or 
longer with 1cm and 0.5cm.Artificial sampling at 0.5 
cm could be done in a total of 46 cases (liver biopsies 
with a size greater than 1.5cm). With the exception of 
1(1.6%) liver biopsy, all other biopsies (45/97.8%) 
showed a decrease in the number of complete portal 
tracts with the mean number of CPTs decreasing from 
7.07 ± 1.73 to 1.30 ± .91. The number of CPT’s ranged 
from a minimum of zero to a maximum of 3. Interface 
hepatitis could be seen in 6(40%) out of 15 cases and 
portal inflammation could be seen in 12(48%) out of 25 
cases in which it was originally seen.Focal necrosis 
could be seen only in 2(13.3%) out of 15 cases.( Chart 
2) 
 
Impact of length of liver biopsy on histopathological 
diagnosis 
As the diagnosis was reviewed after a decrease in the 
biopsy size to 1cm (by artificial sampling), 5 out of 
these 46 biopsies (10.8%) showed a change in 
diagnosis. The diagnosis however remained same in 41 
(89.2%) biopsies. On decreasing the size of the biopsy 
further by 0.5cm , the original diagnosis could be 
maintained in only 26(56.6%) biopsies.These included 
the cases which were initially reported as cirrhosis, 
glycogen storage disease, wilsons disease, few cases of 
cholestatic hepatitis and chronic hepatitis. five (10.8%) 
cases showed a change in diagnosis, all of which were 
that of NASH. In the remaining 15 (32.6%) cases no 
diagnosis was possible at the size of 0.5cm.(Chart 3) 
Impact of length of liver biopsy on ishak’s score 
In addition, artificial sampling at 1cm also resulted in a 
change in the scoring of various diagnoses made.Out of 
the 27 cases of chronic hepatitis which were artificially 
sampled, 11(40.7%) cases showed a decrease in Ishak’s 
score.One-score difference was seen in 10(37%) cases 
and 2-score difference was seen in 1 case(3.7%) .The 
score however  remained same in 16(59.3%) cases. 
Artificial sampling was done in 5 out of 6 cases of 
NASH ,as one case had an initial biopsy size of  
<1.5cm and artificial sampling could not be done in 
it.All these 5 cases showed a decrease in  Kleiner score  
and hence a change in diagnosisOut of 27 cases of 
chronic hepatitis, the Ishak’s score decreased in 17( 
63%) cases.13(48.2%) out of these 17 cases showed a 
2-score difference and 4(14.8%) cases showed a 1-
score difference .Scoring was not possible in 6( 
22.3%)cases owing to the complete loss of complete 
portal tracts after artificial sampling. Five (83.3 %) out 
of six cases of NASH showed a decrease in Kleiner 
score  and hence a change in diagnosis.The scoring was 
not possible in the remaining 1(16.6%) case of NASH 
(Chart 4) 
Impact of length of liver biopsy on fibrosis/staging 
The fibrosis/staging done in a total of 39 cases which 
included chronic hepatitis, primary biliary cirrhosis and 
NASH showed a decrease in stage in 18(46.2 %) 
cases.A 1-stage difference was seen in 14(35.9%) cases 
and a 2-stage difference was seen in 4(10.3%) cases 
whereas the stage remained same in 21(53.8 %) cases. 
The fibrosis/staging was attempted in 39 cases which 
included cases of chronic hepatitis,primary biliary 
cirrhosis and NASH. Out of 39 cases,the stage  
remained same only in 1( 2.6%) case and decreased in 
26(66.7%) cases.3(7.7%) out of 29 cases showed a 1 
stage difference and 23(59%) showed a 2-stage 
difference.Thus there were more cases with a milder 
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stage. However no staging was possible in 12(30.7%) 
cases because of inadequate CPTs and markedly 
reduced liver parenchyma.Only one case had the same 
stage as at 1.5cm(Chart 5) 
Discussion 
This two-year study was conducted in the department 
of Pathology Sher-i-Kashmir Institute of Medical 
Sciences, Soura, Srinagar. The most common clinical 
indication for liver biopsy was chronic hepatitis which 
has also been reported by Sporea et al[9] in their study 
of 250 liver biopsies. Most common histopathological 
diagnosis made in our study was chronic hepatitis (in 
38.6% cases) followed by primary biliary cirrhosis, 
NASH and cirrhosis in 8.5% each. Other 
histopathological diagnoses made included cholestatic 
hepatitis and glycogen storage disease in 7.2% each, 
AIH-PBC overlap in 5.7%, AIH in 4.3% and Wilson’s 
disease in 2.9%. One (1.4%) case reported was 
uncertain for NASH. Because of inadequate size, 
diagnosis was not possible in 7.2% of liver biopsies. 
Khokhar N[10] and Samaila et al[11] have also 
reported chronic hepatitis to be the most common 
histopathological diagnosis in their respective studies 
(68.3% and 40.5% cases respectively). In this study the 
clinical diagnosis was confirmed on histopathological 
examination in 78.5% cases while the histopathological 
diagnosis did not match the clinical diagnosis in 14.3% 
cases. In the study by (Spycher et al)[12], the clinical 
diagnosis was confirmed histopathologically in 84.4% 
of cases and changed in 6.8%. In the study by Gilmore 
et al the diagnosis made clinically was confirmed 
histopathologically in 63% of patients[13].The results 
of this study provide the evidence of a significant 
relationship between biopsy size and histopathological 
diagnosis along with grading and staging of chronic 
viral hepatitis and various other chronic liver 
diseases(in which grading or staging is done).The 
specimens were examined 3 times (at a size of ≥1.5cm, 
at 1cm and finally at 0.5cm).After decreasing the size 
of the biopsy to 1cm, 10.8% cases showed a change in 
diagnosis. All these cases were those of non-alcoholic 
steatohepatitis. The diagnosis however remained same 
in 89.2% cases.On further decreasing the size of 
biopsies to 0.5cm the original diagnosis could be 
maintained in only 56.6% of the biopsies. These 
included the cases which were initially reported as 
cirrhosis, glycogen storage disease, Wilson’s disease, 
and a few cases of cholestatic hepatitis and chronic 
hepatitis. This was because in glycogen storage disease 
and Wilson’s disease, the clinical details provided and 
positive staining for orcein and rhodanine (in Wilson’s) 
and PAS with diastase digestion (in glycogen storage 
disease) were sufficient to make the diagnosis.These 
parameters were least affected by the reduction in size. 
Also the cases of cirrhosis that we diagnosed were all 
micronodular and showed complete replacement of the 
liver parenchyma by regenerative nodules which were 
visible even after reducing the size to 0.5cm. 10.8% 
cases showed a change in diagnosis, all of which had 
the initial diagnosis of NASH. As the score decreased, 
the cases were diagnosed as ‘uncertain for NASH’ or 
‘not NASH’ after the decrease in size. In the remaining 
32.6% cases no diagnosis was possible at the size of 
0.5cm because of either the complete absence of CPTs 
or CPTs showing normal morphology only. Also in 
cases of cholestatic hepatitis and primary biliary 
cirrhosis because of the patchy nature of the biliary 
injury, the diagnosis was impossible when the size and 
hence the complete portal tracts markedly reduced. The 
cases of cholestatic hepatitis which were diagnosed at 
0.5cm had marked cholestasis and showed severe 
ductular destruction in the portal tracts which were 
visible.Our data demonstrates that shorter liver 
specimens result in a significant underestimation of 
both the grade and the stage of the liver disease: In 
assessing the overall grade of necroinflammatory 
activity, the weighted κ score at 1cm and 0.5cm was 
0.447 and 0 respectively indicating poor agreement for 
both. Reducing the length to 1 cm lead to a decrease in 
score of 46.2% of cases with a 1-score difference in 
35.9% cases and a 2-score difference in 10.2% of 
cases. However no change in score was seen in 
53.8%of cases. Further reduction of size to 0.5cm lead 
to a decrease in score of 63% of cases with a 1-score 
difference in 10.8% and 2-score difference in 48.2% 
probably because at 0.5cm most of the biopsies showed 
a complete absence of CPTs or the CPTs showed 
normal morphology only. This indicated that as we 
decrease the size of the biopsy, the score of the disease 
becomes milder and hence results in the 
underestimation of the grade of the disease. Cases with 
severe grades decreased markedly as the specimen size 
was reduced. Colloredo et al in their study also reported 
an almost absence of severe grades in the shorter 
specimens in their study[14].The cases in which the 
fibrosis/staging was done included cases of chronic 
hepatitis, primary biliary cirrhosis and NASH. When 
the fibrosis/staging was done at AS1 there was a 
decrease in stage in 46.2% of the cases. A 1-stage 
difference was seen in 35.9% cases and a 2-stage 
difference was seen in 10.2% cases whereas the stage 
remained same in 53.8% of cases. In the study by 
Schiano et al in a 1-stage difference was seen in 22% 
cases and 6% cases showed a 2-stage difference[15].At 
AS2, staging remained same only in 1(2.6%) case. It 
decreased in 66.7 % cases, with 59% cases showing a 
2-stage difference and 7.7% cases showing a 1-stage 
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difference. However no staging was possible in 30.7% 
of cases because of inadequate CPTs and markedly 
reduced liver parenchyma. In the study by Schiano et 
al, 31% cases showed a 1-stage difference and 13% 
cases showed a 2-stage difference.This indicated a 
milder degree of fibrosis with the decrease in size of 
the biopsy and hence an underestimation of the stage of 
the disease which could hence alter the management of 
the patient.In this study when the specimens size of the 
biopsies originally diagnosed as NASH was reduced, 
there was a significant change in the score, which 
subsequently changed the diagnosis of NASH. The 
fibrosis in these cases was also markedly reduced. This 
was because of the unavailability of parenchyma 
showing steatosis, ballooning and lobular inflammation 
(parameters required for scoring) and decrease in the 
number of portal tracts, which showed inflammation 
and fibrosis. Similar findings were observed when the 
specimen length was reduced in the cases of primary 
biliary cirrhosis. The biopsies showed a marked 
reduction in fibrosis on decreasing the specimen 
length. In assessing the stage of fibrosis, the weighted κ 
score at 1cm and 0.5cm was 0.671 and 0.124 
respectively indicating poor agreement for assessing 
fibrosis at 0. 5 cm. Since closer is the value to 1 better 
is the agreement[5], the agreement for fibrosis was 
better(but not excellent which is for 0.75) with 1cm 
specimens(Table 2) .These studies could comment on 
the larger biopsy specimens which we could not 
because of limited setup. The most important factor 
influencing the diagnostic inadequacy of the smaller 
biopsy sizes is probably the significant decrease in the 
number of complete portal tracts in the smaller 
specimens. Colloredo et al[14], Rocken et al[16] and 
Petz et al[17]reported in their studies that the number 
of complete portal tracts correlated with the size of the 
biopsy. Rocken et al[16], and Vargas-Tank et al 
suggested in their studies that the lower number of 
complete portal tracts may be the reason for the lower 
diagnostic accuracy obtained with smaller 
samples[18].It is widely believed that an adequate liver 
biopsy specimen should contain a minimum number of 
portal tracts. Most pathologists are satisfied with 
specimens containing 6–8 portal tracts [19], although 
some studies now suggest that a greater number of 
portal tracts may be required for adequacy[14]. 
Colloredo et al[14], Zarski et al[20]and Guido et 
al[21]also suggested in their study that a specimen size 
of 2 cm and a minimum of 11 complete portal tracts are 
considered adequate for diagnosis of cirrhosis and 
chronic active hepatitis. Although decreasing the size 
of the biopsy specimen to 1cm did not alter the 
diagnosis, there was a definite change in scoring. There 
was also a decrease in the stage of the disease but the 
agreement was still better as compared to 0.5cm size. 
Further decrease in the size of the biopsy samples to 
0.5cm altered all the three parameters i.e. diagnosis, 
scoring and staging. Infact a considerable number of 
cases (32.6%) the diagnosis was not possible after 
decreasing the sample size to 0.5cm.This was because 
the number of CPTs decreased with decrease in size of 
the biopsy. Our study indicated that at least 7-8 
complete portal tracts should be available to assess the 
different parameters accurately. 
 
 
 
Chart 1: Complete portal tracts at AS1(1cm) 
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Chart 2 : Number of complete portal tracts at AS2(0.5cm) 
 
 
 
Chart 3: Comparison of histological lesions diagnosed at AS1(1cm) and AS2(0.5cm) 
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Chart 4: Comparison of scoring in chronic hepatitis 
 
 
 
Chart 5: Comparison of staging 
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Fig 1 : Photomicrograph of liver biopsy showing altered hepatic architecture with formation of cirrhotic 
nodules.(MTC 10X) 
 
 
 
Fig 2: Non alcoholic steatohepatitis.Photomicrograph of liver biopsy showing steatosis,lobular inflammation 
and fibrotic tendrils.(H&E 10X) 
 
 
 
 
Fig 3: Chronic hepatitis.Liver biopsy showing portal inflammation comprising predominantly of 
lymphocytes.(H&E 40X) 
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Conclusion 
 
The study concluded with the results that a biopsy size 
of less than 1.5cm can be considered inadequate as 
there was definite improvement in the diagnostic 
accuracy at the biopsy size ≥1.5cm when compared to 
1cm and 0.5cm. Also, at least 7-8 complete portal 
tracts should be visualized for accurately diagnosing, 
scoring and staging chronic liver disease. 
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